Fasenra Injection contains Benralizumab 30mg, a monoclonal antibody used for the treatment of severe eosinophilic asthma. It works by targeting and binding to the interleukin-5 receptor alpha on eosinophils, a type of white blood cell involved in the inflammatory process of asthma. By depleting eosinophils, Fasenra helps reduce airway inflammation, leading to improved asthma control and fewer exacerbations. This medication is typically prescribed for patients aged 12 years and older who have a history of severe asthma that is not adequately controlled with standard inhaled corticosteroids and long-acting beta-agonists. Fasenra is administered via subcutaneous injection, usually once every four weeks for the first three doses, followed by maintenance doses every eight weeks. It is important to use Fasenra under the supervision of a healthcare professional experienced in managing severe asthma. Common side effects may include headache, pharyngitis, and injection site reactions. Patients should inform their doctor about any allergies or infections before starting treatment. Fasenra Injection offers a targeted biologic therapy option that can significantly improve quality of life for patients with severe eosinophilic asthma by reducing symptoms and the frequency of asthma attacks.